Background: Before 2002, keloids and intractable hypertrophic scars were treated at our facility with postoperative irradiation of 15 Gy (the traditional protocol). Analysis of the therapeutic outcomes of patients treated with this protocol showed that the recurrence rates of keloids and intractable hypertrophic scars in the anterior chest wall, as well as the scapular and suprapubic regions, were statistically higher than at other sites, while the recurrence rates in earlobes were lower. Thus, we customized doses for various sites. This report describes our trial of postoperative radiation therapy.

Methods: Between January 2002 and September 2004, 109 patients with 121 keloid and intractable hypertrophic scar sites were treated with surgical excision following the new protocol: electron-beam irradiation at total doses of 10, 15, or 20 Gy, depending on the site. The recurrence rates and toxicities were historically followed in 218 patients with 249 keloid and intractable hypertrophic scar sites treated with the old protocol of surgical removal followed by irradiation at 15 Gy (without variation by site). The minimal follow-up time was 18 months. Statistical analysis was performed using Fisher exact probability test.

Results: Total recurrence rates were 29.3% before 2002 and 14.0% after 2003. The recurrence rate in the anterior chest wall was statistically reduced. Outcomes of earlobe did not differ between irradiation with 15 Gy or 10 Gy.

Conclusions: Keloids and intractable hypertrophic scars should be treated with dose protocols customized by site. Our results suggest that keloid and intractable hypertrophic scar sites with a high risk of recurrence should be treated with 20 Gy in 4 fractions over 4 days and that earlobe should be treated with 10 Gy in 2 fractions over 2 days.

Download full-text PDF

Source
http://dx.doi.org/10.1097/SAP.0b013e3180423b32DOI Listing

Publication Analysis

Top Keywords

intractable hypertrophic
24
hypertrophic scars
16
recurrence rates
16
keloids intractable
12
keloid intractable
12
hypertrophic scar
12
scar sites
12
postoperative radiation
8
statistical analysis
8
scars treated
8

Similar Publications

Sodium-glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: A population-based cohort study.

Eur J Prev Cardiol

November 2024

Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Aims: Hypertrophic cardiomyopathy (HCM) is associated with a significant risk of arrhythmia and heart failure (HF), yet treatment options for patients with HCM have remained limited. We aimed to investigate the relationship between sodium-glucose cotransporter-2 inhibitor (SGLT2i) use and clinical outcomes among patients with concurrent HCM and diabetes in real-world settings.

Methods And Results: Using the Korean National Health Insurance Service database, we identified patients with a confirmed diagnosis of HCM and prescriptions for antidiabetic drugs from 2018 to 2022.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore if blocking the CCR2 receptor could prevent pulmonary arterial hypertension (PAH) in rat models and improve inflammatory and vascular issues.
  • Researchers used genetically modified Ccr2(-/-) rats and found that these rats showed lower blood pressure in the heart, reduced inflammation, and less vascular damage after being exposed to certain treatments that typically induce PAH.
  • Additionally, combining the CCR2 blockade with the PDE5 inhibitor tadalafil further improved symptoms of pulmonary hypertension, suggesting a potential therapeutic approach for PAH.
View Article and Find Full Text PDF

This study evaluated the effects of radiofrequency ablation (RFA) eustachian tuboplasty on the treatment of chronic otitis media with effusion (COME), and associated complications, in patients with premature extrusion of the tympanostomy tube (TT). Tuboplasty and T-tube reinsertion were performed in 23 ears with COME, a history of premature TT extrusion, and thickened mucus. Tube retention, perforation closure, hearing improvement, and complications were evaluated.

View Article and Find Full Text PDF
Article Synopsis
  • Giant congenital melanocytic nevus (GCMN) is a noncancerous skin condition that raises concerns about appearance and potential malignancy, necessitating effective treatment options.
  • This report details three cases where GCMN was treated using full-thickness excision paired with cultured epidermal autograft (CEA) and split-thickness skin graft (STSG), achieving nearly complete healing without nevus recurrence.
  • The method showed better results in skin elasticity and minimizing scarring compared to traditional techniques, despite some instances of hypertrophic scars and keloids in certain patients.
View Article and Find Full Text PDF

Delayed onset of hypertrophic cardiomyopathy in a 61-year-old male patient with MYBPC3 mutation.

J Cardiovasc Imaging

August 2024

Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!